A multicenter evaluation of off-label medication use and associated adverse drug reactions in adult medical icus

Critical Care Medicine

Volumn 43, Issue 8, 2015, Pages 1612-1621

  Smithburger, Pamela L ^a   Buckley, Mitchell S ^b   Culver, Mark A ^b   Sokol, Sarah ^c   Lat, Ishaq ^d   Handler, Steven M ^e   Kirisci, Levent ^a   Kane Gill, Sandra L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse drug reaction; Intensive care; Off label drug use; Off label prescribing

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIURETIC AGENT; INSULIN; LAXATIVE; OPIATE; SEDATIVE AGENT; TRIACYLGLYCEROL;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ARTICLE; BLEEDING; CONSTIPATION; DELIRIUM; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; DYSPNEA; ELECTROLYTE DISTURBANCE; EVALUATION STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OTOTOXICITY; PATIENT HARM; PATIENT SAFETY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RASH; RISK FACTOR; SEIZURE; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SEX; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INCIDENCE; INTENSIVE CARE UNIT; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; OFF-LABEL USE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84942531746     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001022     Document Type: Article

References (65)

1. Gazarian M, Kelly M, McPhee JR, et al: Off-label use of medicines: Consensus recommendations for evaluating appropriateness. Med J Aust 2006; 185:544-548
2. U. S. Food and Drug Adminstration: New Drug Application (NDA). Available at: http://www. fda. gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ NewDrugApplicationNDA/. Accessed January 20, 2014
3. Blum RS: Legal considerations in off-label medication prescribing. Arch Intern Med 2002; 162:1777-1779
4. Gillick MR: Controlling off-label medication use. Ann Intern Med 2009; 150:344-347
5. Stafford RS: Regulating off-label drug use-Rethinking the role of the FDA. N Engl J Med 2008; 358:1427-1429
6. Radley DC, Finkelstein SN, Stafford RS: Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166:1021-1026
7. Barr J, Brenner-Zada G, Heiman E, et al: Unlicensed and off-label medication use in a neonatal intensive care unit: A prospective study. Am J Perinatol 2002; 19:67-72
8. Phan H, Leder M, Fishley M, et al: Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department. Pediatr Emerg Care 2010; 26:424-430
9. Jong GW, Vulto AG, de Hoog M, et al: Unapproved and off-label use of drugs in a children's hospital. N Engl J Med 2000; 343:1125-1126
10. Eastman P: Reimbursement policies discourage off-label drug use. Oncol Times 2005; 27:8-10
11. Lat I, Micek S, Janzen J, et al: Off-label medication use in adult critical care patients. J Crit Care 2011; 26:89-94
12. Seynaeve S, Verbrugghe W, Claes B, et al: Adverse drug events in intensive care units: A cross-sectional study of prevalence and risk factors. Am J Crit Care 2011; 20:e131-e140
13. Kane-Gill SL, Kirisci L, Verrico MM, et al: Analysis of risk factors for adverse drug events in critically ill patients. Crit Care Med 2012; 40:823-828
14. Kane-Gill SL, Jacobi J, Rothschild JM: Adverse drug reactions in intensive care units: Risk factors, impact, and the role of the team care. Crit Care Med 2010; 38(6 Suppl):S83-S89
15. Albaladejo P, Caillet B, Moine P, et al: [Off-label prescriptions in an adult surgical intensive care unit]. Presse Med 2001; 30:1484-1488
16. Institute for Safe Medication Practices: ISMP'S List of High Alert Medications. Available at: http://www. ismp. org/tools/highalertmedications. pdf. Accessed August 5, 2012
17. DRUGDEX: MICROMEDEX Healthcare Series. Greenwood, CO, Thomson Reuter, 2011
18. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
19. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
20. Kramer MS, Leventhal JM, Hutchinson TA, et al: An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979; 242:623-632
21. Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245
22. Jones JK: Definition of events associated with drugs: Regulatory perspectives. J Rheumatol Suppl 1988; 17:14-19
23. Kane-Gill SL, Visweswaran S, Saul MI, et al: Computerized detection of adverse drug reactions in the medical intensive care unit. Int J Med Inform 2011; 80:570-578
24. Harinstein LM, Kane-Gill SL, Smithburger PL, et al: Use of an abnormal laboratory value-drug combination alert to detect drug-induced thrombocytopenia in critically ill patients. J Crit Care 2012; 27:242-249
25. Rivkin A: Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 2007; 64: 1840-1843
26. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3. 0. Bethesda, National Cancer Institute, 2010
27. MEDMARX: Medication Error Data Entry Form. The United States Pharmacopeia Convention, 2005
28. Kane-Gill SL, Kowiatek JG, Weber RJ: A comparison of voluntarily reported medication errors in intensive care and general care units. Qual Saf Health Care 2010; 19:55-59
29. National Coordinating Council on Medication Error Reporting and Prevention: NCC MERP Index for Categorizing Medication Errors. Available at: http://www. nccmerp. org/pdf/indexColor2001-06-12. pdf. Accessed May 27, 2008
30. Hosmer DW, Lemeshow A: Applied Logistic Regression. Second Edition. New York, NY, John Wiley and Sons, 2000
31. University of Michigan Health System: Management of Acute Atrial Fibrillation and Atrial Flutter in Non-pregnant Hospitalized Adults. Ann Arbor, MI, University of Michigan Health System, 2014, 26 p
32. January CT, Wann LS, Alpert JS, et al; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1-e76
33. National Clinical Guideline Venter: Atrial Fibrillation: The Management of Atrial Fibrillation. London, UK, National Institute for Health and Care Excellence (NICU), 2014, 49 p (Clinical guideline; no. 180)
34. Bushnell C, McCullough L: Stroke prevention in women: Synopsis of the 2014 American Heart Association/American Stroke Association guideline. Ann Intern Med 2014; 160:853-857
35. Culebras A, Messé SR, Chaturvedi S, et al: Summary of evidencebased guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82:716-724
36. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41:263-306
37. National Clinical Guideline Centre for Acute and Chronic Conditions: Alcohol-Use Disorders. Diagnosis and Clinical Management of Alcohol-Related Physical Complications. London, UK, National Institute for Health and Clinical Excellence (NICE), 2010, 30 p (Clinical guideline; no. 100)
38. Sveum R, Bergstrom J, Brottman G, et al: Diagnosis and Management of Asthma. Bloomington, MN, Institute for Clinical Systems Improvement, 2012
39. Lalloo UG, Ainslie GM, Abdool-Gaffar MS, et al; South African Thoracic Society: Guideline for the management of acute asthma in adults: 2013 update. S Afr Med J 2013; 103:189-198
40. Umpierrez GE, Hellman R, Korytkowski MT, et al; Endocrine Society: Management of hyperglycemia in hospitalized patients in non-critical care setting: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:16-38
41. Surawicz CM, Brandt LJ, Binion DG, et al: Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-498; quiz 499
42. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455
43. McKay SL, Fravel M, Scanlon C: Management of Constipation. Iowa City, IA, University of Iowa Gerontological Nursing Interventions Research Center, Research Translation and Dissemination Core, 2009, 51 p
44. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2014), Executive Summary. 2014. Available at: http://www. goldcopd. org/. Accessed March 30, 2015
45. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
46. Bodmann KF: Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 2005; 51:227-233
47. National Institute for Health and Clinical Excellence (NICE): Acute Upper Gastrointestinal Bleeding: Management. London, UK, National Institute for Health and Clinical Excellence (NICE), 2012, 23 p (Clinical guideline; no 141)
48. University of Texas at Austin School of Nursing, Family Nurse Practitioner Program: Clinical Guideline for the Treatment of Primary Insomnia in Middle-Aged and Older Adults. Austin, TX, University of Texas at Austin, School of Nursing, 2014, 28 p
49. Guideline Development Group for the Management of Patients With Insomnia in Primary Care: Clinical Practice Guidelines for the Management of Patients With Insomnia in Primary Care. Madrid, Spain, Health Technology Assessment Unit, Lain Entralfo Agency, Ministry of Health, Social Services and Equality (Spain), 2009, 159 p
50. Pandolfini C, Impicciatore P, Provasi D, et al; Italian Paediatric Offlabel Collaborative Group: Off-label use of drugs in Italy: A prospective, observational and multicentre study. Acta Paediatr 2002; 91:339-347
51. Pandolfini C, Bonati M: A literature review on off-label drug use in children. Eur J Pediatr 2005; 164:552-558
52. Kane-Gill SL, Van Den Bos J, Handler SM: Adverse drug reactions in hospital and ambulatory care settings identified using a large administrative database. Ann Pharmacother 2010; 44:983-993
53. Rothschild JM, Landrigan CP, Cronin JW, et al: The Critical Care Safety Study: The incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med 2005; 33:1694-1700
54. Cullen DJ, Sweitzer BJ, Bates DW, et al: Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units. Crit Care Med 1997; 25:1289-1297
55. Benkirane RR, Abouqal R, Haimeur CC, et al: Incidence of adverse drug events and medication errors in intensive care units: A prospective multicenter study. J Patient Saf 2009; 5:16-22
56. Anthes AM, Harinstein LM, Smithburger PL, et al: Improving adverse drug event detection in critically ill patients through screening intensive care unit transfer summaries. Pharmacoepidemiol Drug Saf 2013; 22:510-516
57. Stockwell DC, Kane-Gill SL: Developing a patient safety surveillance system to identify adverse events in the intensive care unit. Crit Care Med 2010; 38:S117-S125
58. Leape LL, Cullen DJ, Clapp MD, et al: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282:267-270
59. Goh CL: An approach to the evaluation and documentation of adverse drug reaction. Sing Med J 1989; 30:285-289
60. Baughman RP, Meyer KC, Nathanson I, et al: Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 142:e1S-e111S
61. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
62. Rosendorff C: Hypertension and coronary artery disease: A summary of the American Heart Association scientific statement. J Clin Hypertens (Greenwich) 2007; 9:790-795
63. Luehr D, Woolley T, Burke R, et al: Hypertension Diagnosis and Treatment. Bloomington, MN, Institution for Clinical Systems Improvement (ICSI), 2012, 67 p
64. National Institute for Health and Care Excellence (NICE): Neuropathic Pain-Pharmacological Management. The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist Settings. London, UK, National Institute for Health and Care Excellence (NICE), 2013, 41 p (Clinical guideline; no. 173)
65. Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113-1e88